Nicole Haas
Medical · Cranberry Township, PANPI 1255682043
Payments from drug & device makers
Across 2,067 payments — averaging $22.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mindera Corp$7K
- Amgen$7K
- Johnson & Johnson$6K
- AbbVie$5K
- UCB, Inc.$3K
- Daiichi Sankyo Inc.$2K
- plus $16K from 40 others
What the payments were for
- Consulting fees$7,00015%
- Speaking & faculty fees$8002%
- Food & beverage$37,57983%
- Education$1690%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RAYOS$2,400
- Rinvoq$371
- INJECTAFER$222
- Skyrizi$122
- PURIFIED CORTROPHIN GEL$120
- Tremfya$119
- SIMPONI ARIA$119
- TALTZ$114
- Bimzelx$114
- Cimzia$103
How this compares
$45,548 in reported general payments places this provider in the 95th percentile of 2,594 medical providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 65 | $457,267 |
| Enbrel SureclickEtanercept | 30 | $262,008 |
| Cimzia (2 Pack)Certolizumab Pegol | 27 | $146,800 |
| OtezlaApremilast | 25 | $122,503 |
| Humira(Cf) PenAdalimumab | 12 | $106,197 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 13 | $96,220 |
| Enbrel MiniEtanercept | 13 | $95,541 |
| Xeljanz XrTofacitinib Citrate | 16 | $91,406 |
| Actemra ActpenTocilizumab | 17 | $89,163 |
| ProliaDenosumab | 39 | $67,926 |
| KevzaraSarilumab | 13 | $56,153 |
| Hydroxychloroquine Sulfate | 463 | $22,750 |
| OtrexupMethotrexate/Pf | 25 | $18,585 |
| Buprenorphine | 17 | $7,924 |
| Diclofenac Sodium | 26 | $7,201 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $4,600 | $457,26765 claims |
| AmgenOtezla, Prolia | $6,513 | $190,42964 claims |
| UCB, Inc.Cimzia (2 Pack) | $2,627 | $146,80027 claims |
| Antares Pharma, Inc.Otrexup | $15 | $18,58525 claims |
| Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate | $61 | $8,46633 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,594 medical providers in Pennsylvania.
Other medical in Cranberry Township
- Jacqueline KernaghanSpringfield$427K
- Drew SodaNew Hope$220K
- Angela KapalkoPhiladelphia$123K
- Linda PerryPhiladelphia$123K
- Cory DavidsonErie$119K
- Shelley SassamanTamaqua$90K
- Meghan HoffnerBethlehem$86K
- Thomas IacovoniDanville$72K
- Scott CoxWynnewood$66K
- Sarah SmithPhiladelphia$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.